<DOC>
	<DOCNO>NCT01423643</DOCNO>
	<brief_summary>The chief purpose research understand antiretroviral therapy ( ART ) affect progression liver disease person co-infected HIV hepatitis C virus ( HCV ) . The investigator study liver disease progression cohort dually infected person accord success ART .</brief_summary>
	<brief_title>HCV/HIV Coinfection : Antiviral Therapy Fibrosis</brief_title>
	<detailed_description>Enrolled subject complete questionnaire concern health status , lifestyle , alcohol/drug use . Participants undergo liver elastography every 6-12 month .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>CoInfected Arm 1 . Subject must HIV/HCV coinfected adult HIV infection diagnose antibody test chronic HCV infection diagnose reactive HCV antibody detectable plasma HCV RNA . 2 . Subject must receive medical care JHU HIV clinic Viral Hepatitis Center . 3 . Subjects previously enrol study cohort , currently receive care Moore Clinic , may continue study . 4 . Females childbearing potential must willing undergo urine serum pregnancy test . 5 . Subject must able provide informed write consent . Control Arm 1 . Subject must risk medical condition increase risk liver disease . These include , limited , HIV monoinfection , HCV monoinfection , Hepatitis B infection , alcohol addiction , and/or nonalcoholic steatohepatitis . 2 . Females childbearing potential must willing undergo urine serum pregnancy test . 3 . Subject must able provide informed write consent . 1 . To avoid risk associate ionize radiation , female subject may pregnant breast feeding time DEXA scanning . To avoid unknown risk fetus , female subject may pregnant time liver biopsy FibroScan . 2 . To avoid interference DEXA scan , subject may undergo nuclear medicine exam past week and/or may undergo xray procedure contrast solution within past 72 hour . 3 . To avoid unknown risk , subject implant cardiac device defibrillator pacemaker may undergo FibroScan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>AIDS Virus</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>Virus , Human Immunodeficiency</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , chronic</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Hepatitis C antibody</keyword>
	<keyword>Hepatitis C antigen</keyword>
</DOC>